Preclinical Proof of Concept for a personalized SNAP <sup>TM</sup> -TIL (Specific Neo-Antigen Peptides -TIL) therapy platform
Tithi Ghosh(Translational Genomics Research Institute), Sunil Sharma, Taylor Bargenquast(HonorHealth), Mohan R. Kaadige(University of Utah), Saul J. Priceman(City of Hope), Trason Thode(Translational Genomics Research Institute), Serina Ng(Translational Genomics Research Institute), Michael W. Gordon(HonorHealth), Jorge Soria‐Bustos(Translational Genomics Research Institute), Raffaella Soldi(Translational Genomics Research Institute), Erkut Borazanci(HonorHealth), Ryan Rodriguez del Villar(Translational Genomics Research Institute), Yan Xing(City Of Hope National Medical Center), Justin C. Moser(HonorHealth), Erin Kelley(Translational Genomics Research Institute), Stephen J. Forman(City of Hope), John A. Altin(Translational Genomics Research Institute), Frank Tsai(HonorHealth), Alexis Weston(Translational Genomics Research Institute)
Cited by 0
Related Papers
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer
|JAMA Oncology|2019|289
Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)
|Clinical Cancer Research|2019|260
Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses
|Cell Reports Medicine|2021|219
PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages
|Journal for ImmunoTherapy of Cancer|2022|111